Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2012-12-02 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Oxycodone Patch Update - Development and Product Expansion 3 pages 51.8KB
Regulatory Filings Classification · 95% confidence The document is a detailed update from Phosphagenics Limited about its opioid patch development program, including clinical trial plans, product expansion, and strategic development. It discusses resolved technical issues, clinical trial timelines, and commercial strategy. The content is a corporate announcement providing progress and future plans rather than a formal financial report, earnings release, or regulatory filing. It does not contain financial statements, voting results, or management changes. The document length is 6439 characters, which is relatively short and reads like a press release or market announcement. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous corporate announcements that do not fit other specific categories.
2012-12-02 English
Reconciliation - Non-Quoted Conditional Rights 13 pages 201.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) new issue announcement form. It details changes in the number of non-quoted conditional rights, including lapses and new issues, and provides information about the securities issued, their terms, and compliance with ASX rules. The document is regulatory in nature, announcing changes in capital structure and securities issued, but it is not a full financial report, earnings release, or management discussion. It is a formal announcement related to capital changes and securities issuance, specifically a new issue announcement and application for quotation of additional securities. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS) fallback, but a formal capital change filing.
2012-11-15 English
POH in JV to Supply TPM Equine Supplements to Golbal Market 2 pages 49.1KB
Regulatory Filings Classification · 90% confidence The document is a company announcement dated 31 October 2012 about a joint venture to supply equine supplements using proprietary technology. It discusses product launches, approvals, manufacturing plans, and distribution arrangements. There is no financial data, regulatory filing references, or report attachments. The content is a business update or press release about a commercial partnership and product launch rather than a financial report, regulatory filing, or management announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2012-10-30 English
POH Licences TPM Platform to Indian Pharmaceutical Company 2 pages 60.3KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement about Phosphagenics licensing its TPM platform technology to an Indian pharmaceutical company. It discusses the licensing agreement, upfront fees, royalties, and the business context. There are no financial statements, regulatory filings, or detailed financial data. The document is a press release announcing a business development or partnership, which fits best under Capital/Financing Update (CAP) as it relates to licensing and potential revenue streams. The document length is 4572 characters, which is short and typical for an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2012-10-29 English
Presentation - Macquarrie Emerging Healthcare Conference 24 pages 956.4KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Phosphagenics at the Macquarie Annual Emerging Healthcare Conference in October 2012. It focuses on the company's technology platform (TPM®), pharmaceutical and personal care applications, clinical trial progress, partnerships, and commercial strategy. The content is structured as a slide deck with forward-looking statements, company overview, technology details, pipeline updates, and value drivers. There are no financial statements, regulatory filings, voting results, or management changes. The document is clearly an investor-focused presentation detailing financials, strategy, and market position. Therefore, it fits the definition of an Investor Presentation (IP). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2012-10-09 English
September 2012 Newsletter 10 pages 2.9MB
Investor Presentation Classification · 85% confidence The document is a detailed newsletter from September 2012 addressed to shareholders, discussing various business updates, product development progress, partnerships, and market outlooks. It includes operational highlights, commercial arrangements, and strategic plans but does not contain formal financial statements, audit opinions, or regulatory filings. It is not a formal annual or interim report, earnings release, or regulatory announcement. The content is more akin to a shareholder update or company newsletter providing business progress and outlook information. Given the nature and length of the document, it fits best into the category of an Investor Presentation (IP) or a Management Report (MDA). However, since it is a newsletter format with broad business updates rather than a formal management discussion and analysis of financial results, it aligns more closely with an Investor Presentation (IP) which often includes strategic and operational updates for investors. Therefore, the most appropriate classification is Investor Presentation (IP).
2012-09-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.